Allied Market Research

2024

Rubella Vaccine (human Diploid Cell) Market

Rubella Vaccine (Human Diploid Cell) Market Size, Share, Competitive Landscape and Trend Analysis Report by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Rubella is an acute, viral, and contagious infection, which has a mild effect on children, and is caused by the transmission of airborne droplets of infected people through sneezing or coughing. However, pregnant women suffering from rubella have to face severe consequences, as the viral infection results in death or congenital defects known as congenital rubella syndrome (CRS). Rubella vaccine has gained traction over the years as the disease is preventable only through vaccination and no other specific treatments exist for it. The major factors that fuel the growth of the market are increase in incidence of rubella infection globally Approximately 100,000 infants are affected by rubella annually, thus increasing the government focus on rubella vaccination, which further propels the market growth. However, inherent disadvantages of using human diploid cell technology for constructing rubella vaccine such as, high selectivity and insufficient yield, restrain the growth of market. Conversely, ongoing R&D activities for the advancement of rubella vaccines are expected to offer lucrative opportunities for the growth of the market.

The report segments the market on the basis of end user and region. Based on end user, the market is divided into hospitals, clinics, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in this report are Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).

Key Benefits

  • The study provides an in-depth analysis of the global rubella vaccine (human diploid cell) market with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis¬†to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by type assists to understand the various forms of rubella (human diploid cell) vaccines available.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

Rubella Vaccine (Human Diploid Cell) Market Report Highlights

Aspects Details
icon_5
By End User
  • Pediatric Rubella (Human Diploid Cell) Vaccine
  • Traveler Rubella (Human Diploid Cell) Vaccine
  • Adult Rubella (Human Diploid Cell) Vaccine
icon_6
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_7
Key Market Players

Chiron Corporation (Novartis), Berna Biotech, Astellas Pharma Inc., Serum Institute of India, Merck & Co. Inc., Pfizer Inc., Sanofi-Aventis, CSL Limited, GlaxoSmithKline Plc, AstraZeneca Plc.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Rubella Vaccine (Human Diploid Cell) Market

Global Opportunity Analysis and Industry Forecast, 2023-2032